CD8A and cancer: The PD-1/PD-L1 pathway promotes a hyporesponsive T-cell response, resulting in anergy (diminished antigen response) and apoptosis of CD8+ T-cells, thereby protecting cancer cells from direct cytotoxic attack [20].